The invention belongs to the technical field of biological
medicine, and particularly relates to a
molecular marker IDO1 and application thereof in
breast cancer treatment. Through fat
cell induction,
bioinformatics analysis,
small interfering RNA knock-down,
tryptophan acid metabonomics, LC-MS / MS and other
experimental methods, the regulation and
control effect of the WNT10B-IDO1 axis on tumor-related fat
cell tryptophan metabolism and the
molecular mechanism of the regulation and
control effect on the tumor
promotion effect of the WNT10B-IDO1 axis are deeply explored. The invention discloses high expression of IDO1 in
breast cancer related fat cells for the first time, and finds that
breast cancer cells regulate and control the IDO1 level and
tryptophan metabolism of tumor related fat cells through a WNT10B-
beta catenin signal axis. By inhibiting expression of
breast cancer cells WNT10B or inhibiting expression of IDO1 in tumor-associated adipocytes, tryptophan
metabolic disorder of the tumor-associated adipocytes can be inhibited, dedifferentiation characteristics of the tumor-associated adipocytes are inhibited, tumor malignant phenotypes are finally inhibited, and treatment of breast
cancer is realized. Therefore, the invention provides a new direction for prevention and treatment of breast
cancer.